top of page
Executive Spotlights

Bavarian Nordic to buy Emergent BioSolution’s travel vaccine portfolio for up to $380 mln

Durham, NC, February 15, 2023 (Reuters) -- Danish pharmaceuticals company Bavarian Nordic has agreed to buy a portfolio of travel vaccines from Emergent BioSolutions Inc for up to $380 million, it said on Wednesday after delivering an upbeat outlook for 2023.

Read full article here.

Recent Posts

See All
Life Science Headlines
bottom of page